Market revenue in 2023 | USD 2,091.5 million |
Market revenue in 2030 | USD 3,771.7 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.04% in 2023. Horizon Databook has segmented the Asia Pacific blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
For instance, Kura Oncology's ongoing clinical trial for tipifarnib, a pipeline candidate being investigated for treating peripheral T-cell lymphoma, demonstrates the company's commitment to advancing innovative therapies for patients. There has been a growing interest and investment in developing liquid biopsy tests for blood cancers in Asia.
Furthermore, players in the region are focusing on advancements in genomic profiling and precision medicine, leading to the development of targeted diagnostic tests that can identify specific genetic mutations or biomarkers associated with blood cancers. This information can guide personalized treatment decisions.
Overall, the Asia Pacific blood cancer diagnostics market is expected to grow significantly due to the increasing prevalence of blood cancers, advancements in diagnostic technologies, and growing healthcare expenditure. Key countries in the region include Japan, China, India, South Korea, Thailand, and Australia.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific blood cancer diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account